Company Overview

Amphivena Therapeutics, Inc. is a private immuno-oncology company that is developing selective T cell engagers for the treatment of hematologic and solid tumors.  Our lead therapeutic candidate, AMV564, is a bivalent CD33/CD3 T cell engager that eliminates immature, immune-suppressive myeloid cells, including MDSC, which potently suppress T cells and antigen presenting cell (APC) function and are associated with poor prognosis in cancer patients.    

Leadership

Curtis L Ruegg

Curtis L. Ruegg, Ph.D.

CEO & President 

Victoria Smith

Victoria Smith, Ph.D.

Chief Scientific Officer

Patrick Chun

Patrick Chun, M.D.

Vice President

Clinical Development

Amy Penticoff

Amy penticoff, MBA

Vice President

Technical Operations

Board of Directors

Peter Van Vlasselaer

Peter Van Vlasselaer, Ph.D.

Executive Chairman

Eric Moessinger

Eric Moessinger

NanoDimension

Mark McDade

Mark McDade

Qiming Venture Partners USA

Luke Evnin

Luke Evnin, Ph.D.

MPM Capital

Christian Richard

Christian Richard

Tekla Capital Management LLC

Curtis L. Ruegg

Curtis L. Ruegg, Ph.D.

CEO & President

SCIENTIFIC ADVISORY BOARD

John F. DiPersio

John F. DiPersio, M.D., Ph.D.

Gail J Roboz

Gail J. Roboz, M.D.

Jorge Cortes

Jorge Cortes, M.D.

Alan F List

Alan F. List, M.D.

Roland B Walter

Roland B. Walter, M.D., Ph.D.

Guillermo Garcia-Manero

Guillermo Garcia Manero, M.D.

Mario Sznol

Mario Sznol, M.D.